Other reports show that TILs is a significant predictor of the pathologic complete response in patients with triple-negative (TN) and human epidermal growth factor receptor-2 (HER2) positive breast cancer subtypes [13, 14]. This evidence concerns the gene ERBB2 and breast cancer.